Latest News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
12/23/15AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency
REDWOOD CITY, Calif., Dec. 23, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centr... 
Printer Friendly Version
12/14/15AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
- AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016 - FDA Agrees to Include a Significant Number of Patients from the Zalviso Studies into the ARX‑04 Safety Database REDWOOD CITY, Calif., Dec. 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for the treatment of acute pain, today reported on the outcome of th... 
Printer Friendly Version
11/23/15AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 23, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that AcelRx Co-founder and Chief Medical Officer Pamela Palmer and Chief Financial Officer Tim Morris will be presenting at Piper Jaffray 27th Annual Healthcare Conference in New York.  Details of the conference are as follows: Piper Jaffray 2... 
Printer Friendly Version
11/19/15AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting
REDWOOD CITY, Calif., Nov. 19, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will be made at the Emerging Technology session of the American Society of Regional Anesthesia and Pain Medicine (ASRA) 14th Annual Pain Medicine Meeting to be held November 19th to November 21st at the Fontai... 
Printer Friendly Version
11/10/15AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 10, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris will be presenting at the Jefferies 2015 Global Healthcare Conference in London. Details of the conference are as follows: Jefferies 2015 Global Healthcare Conference Date:  Thursday, November 19 Loca... 
Printer Friendly Version
11/05/15AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 5, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris will be presenting at the Credit Suisse 24th Annual Healthcare Conference in Phoenix, AZ.  Details of the conference are as follows: Credit Suisse 24th Annual Healthcare Conference 2015  Date:  Wednesda... 
Printer Friendly Version
11/04/15AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients
REDWOOD CITY, Calif., Nov. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, will be presenting at ObesityWeek 2015 an analysis from three Phase 3 studies showing that Zalviso™ (sufentanil sublingual tablet system 15 mcg) provides a faster onset of pain relief in obese (BMI ≥ 30 kg/m2) post-surgical patients than intravenous (IV) patient-... 
Printer Friendly Version
10/29/15AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results
REDWOOD CITY, Calif., Oct. 29, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and nine months ended September 30, 2015. Business highlights include: On September 9, 2015, AcelRx announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and... 
Printer Friendly Version
10/26/15AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call and Webcast on Thursday, Oct 29th, 2015
REDWOOD CITY, Calif., Oct 26, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release Third Quarter financial results after market close on Thursday, Oct 29th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Oct 29th, 2015 to discus... 
Printer Friendly Version
10/23/15AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting
Presentation of Clinical Data from Recently Completed Phase 3 Study in Ambulatory Surgery Patients Highlights Efficacy and Tolerability of ARX-04 30 mcg REDWOOD CITY, Calif., Oct. 23, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the 2015 Annual Meeting of the American Society of Anesthesiologists (Anesthesiology 2015) to be held October 24th to October 28th at the San Diego Convention Center in San Diego, CA.  For nearly ... 
Printer Friendly Version
10/09/15AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting
Clinical Data from Phase 2 and Phase 3 Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient Surgical Populations REDWOOD CITY, Calif., Oct. 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European Society of Emergency Medicine (EuSEM) meeting to be held October 11thth to October 14th, 2015 at the Lingotto Congress Centre in Turin, Italy.  The annual EuSEM is the large... 
Printer Friendly Version
10/08/15AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif., Oct. 8, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso™ (sufentanil sublingual tablet system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting.  The company has received formal minutes of the telephonic meeting held in... 
Printer Friendly Version
10/06/15AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., Oct. 6, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The pri... 
Printer Friendly Version
10/01/15AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy
REDWOOD CITY, Calif., Oct. 1, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Gina Ford, RPh to the role of Vice President of Commercial Strategy. Ms. Ford has worked with AcelRx as a consultant from 2013 to the present and has been instrumental in the development of a commercial strategy for Zalviso™ (su... 
Printer Friendly Version
09/24/15AcelRx Pharmaceuticals to Host Analyst & Investor Event on October 2, 2015
REDWOOD CITY, Calif., Sept. 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company will host an Analyst & Investor Day on Friday, October 2 in New York from 12:00pm – 2:00pm ET. Members of the management team will discuss the AcelRx late-stage product candidates, Zalviso™ and ARX-04. A comprehensive up... 
Printer Friendly Version
09/22/15AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso™ for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
Approval triggers $15 million milestone payment to AcelRx from Grunenthal REDWOOD CITY, Calif., Sept. 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) announced today that the European Commission (EC) has approved Zalviso™ (15 micrograms sufentanil sublingual tablets) for the management of acute moderate-to-severe post-operative pain in adult patients. The marketing authorization is granted for the 28 EU member states as well as for the European Economic Area (EEA... 
Printer Friendly Version
09/21/15AcelRx Pharmaceuticals Receives $65 Million from the Partial Sale of Zalviso™ European Royalties and Commercial Milestones to PDL BioPharma
REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH.  Gross proceeds from the sale are $65 million from... 
Printer Friendly Version
09/09/15AcelRx Pharmaceuticals' ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain
Detailed SAP301 Results to be Presented at the American Society of Anesthesiologists Annual Meeting October 24-28, 2015 in San Diego, CA. REDWOOD CITY, Calif., Sept. 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints i... 
Printer Friendly Version
08/26/15AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September
REDWOOD CITY, Calif., Aug. 26, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at BioCentury NewsMakers Conference and the Rodman and Renshaw 17th Annual Global Investment Conference and participating at FBR Second Annual Healthcare Conference. Details of the three ... 
Printer Friendly Version
08/03/15AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results
REDWOOD CITY, Calif., Aug. 3, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and six months ended June 30, 2015. Business highlights include: On July 23, 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Zalvi... 
Printer Friendly Version
07/29/15AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015.
REDWOOD CITY, Calif., July 29, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release Second Quarter financial results after market close on Monday, Aug 3rd, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Aug 3rd,... 
Printer Friendly Version
07/24/15AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
REDWOOD CITY, Calif., July 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual tablets). The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational dru... 
Printer Friendly Version
07/02/15Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., July 2, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.  IAP... 
Printer Friendly Version
05/22/15AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June
REDWOOD CITY, Calif., May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive officer Howie Rosen will be presenting at Jefferies 2015 Healthcare Conference and chief financial officer Tim Morris will be presenting at JMP Securities Life Science Conference. Details of the two pr... 
Printer Friendly Version
05/14/15AcelRx Awarded Contract from Department of Defense to Advance ARX-04
REDWOOD CITY, Calif., May 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced it has entered into Contract No. W81XWH-15-C-0046 worth up to $17.0 million, supported by the United States Army Medical Research and Materiel Command (USAMRMC) within the U.S. Department of Defense (DoD). The contract provides partial f... 
Printer Friendly Version
05/04/15AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results
REDWOOD CITY, Calif., May 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on Zalviso and reported financial results for the three months ended March 31, 2015. Zalviso Regulatory Update On April 21, 2015, AcelRx submitted a request to the Division of Anesthesia, Analgesia, and Add... 
Printer Friendly Version
05/01/15AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer  will be participating in three upcoming investor events.  Details of the events are as follows: Mizuho Third Annual Healthcare Corporate Access Day Date: Tuesday, May 5 Location:  The Omni Ber... 
Printer Friendly Version
04/30/15AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015
REDWOOD CITY, Calif., April 30, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release First Quarter financial results after market close on Monday, May 4th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 4th,... 
Printer Friendly Version
04/14/15AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting
Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY, Calif., April 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting to be held April 15th to April 18th, 2015 at the Gaylord Opryland Resort and Convention... 
Printer Friendly Version
03/20/15AcelRx Appoints Howard B. Rosen as Interim CEO
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1, 2015. Mr. Ros... 
Printer Friendly Version
03/16/15AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif., March 16, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufenta... 
Printer Friendly Version
03/09/15AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three and twelve months ended December 31, 2014.     Fourth Quarter 2014 Financial Results Net loss for the fourth quarter of 2014 was $13.8 million, or $0.32 basic and diluted net loss per share, compared... 
Printer Friendly Version
03/09/15AcelRx Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and potential content of the resubmission of the New Drug Application ("NDA") for Zalviso. AcelRx late last week received correspondence from the Food and Drug Administration ("FDA") stating that in addition to... 
Printer Friendly Version
03/04/15AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015
REDWOOD CITY, Calif., March 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter and yearly 2014 financial results after market close on Monday, March 9th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific... 
Printer Friendly Version
02/20/15AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at RBC Capital Markets' Global Healthcare Conference and Cowen and Company's 35th Annual Healthcare Conference.  Details of the two presentations are as follows: ... 
Printer Friendly Version
02/04/15AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows: BIO CEO & Investor Conference Dat... 
Printer Friendly Version